Summary
The effect produced on tumor progression by the injection of either VCN-treated tumor cells or tumor cells mixed with VCN to dogs with spontaneous mammary tumors was investigated. Dogs of different breeds and ages with at least two palpable spontaneous mammary tumors were selected. One tumor was left in the animal for further clinical examination, whereas the other tumor(s) was (were) excised for histologic diagnosis and for preparation of a single-cell suspension. Autologous M-cells were treated with VCN, subsequently extensively washed and injected SC into the neck of the dog on the day of operation and on the next day or different numbers of autologous M tumor cells (105, 106, 107, 5×107, 108) were mixed with different amounts of VCN (0, 0.65, 6.5, 65 mU), and these various mixtures were injected ID at different sites to each dog on the day of operation. This procedure has been called chessboard vaccination (Seiler and Sedlacek, 1978). Altogether 79 dogs were blindly distributed into six groups in three consecutive studies. The results show that the therapeutic effect of the injection of VCN-treated autologous tumor cells depends on the number of tumor cells injected: injection of 2×107 tumor cells repeatedly induced regression of the residual tumor mass (Studies I, II, and III) in most dogs and prevention of metastasis (Study I), while the application of 1×108 tumor cells caused enhanced tumor proliferation in all and early metastasis in most of the dogs (Study I). The injection of 2×106 tumor cells induced only a transient regression, with subsequent progression of the residual mammary tumor (Study II). Repetition of the injection of 2×106 tumor cells three times every 4 weeks did not improve this effect (Study II). The chessboard vaccination proved to be at least as effective as the injection of 2×107 VCN-treated tumor cells (Study III), although 1×108 or more tumor cells had been injected; this number of cells caused tumor enhancement when the cells were treated with VCN only and injected SC (Study I). Moreover, the DTH reaction after ID injection of autologous tumor cells could be increased by the addition of VCN: low numbers of tumor cells and high amounts of VCN or high numbers of tumor cells and low amounts of VCN caused the most pronounced skin response. The relevance of these data to overcoming the risk of tumor enhancement after injection of an inadequate number of VCN-treated tumor cells and the possible diagnostic and therapeutic relevance of the DTH response after chessboard vaccination will be discussed.
Similar content being viewed by others
References
Albright, L., Madigan, J. C., Gaston, M. R., Houchens, D. P.: Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guérin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res. 35, 685 (1975).
Aminoff, D.: Methods for the quantitative examination of N-acetylneuraminic acid and their application to hydrolysates of sialmucoids. Biochem. J. 81, 384 (1961).
Bekesi, J. G., St. Arenault, G., Walter, L., et al.: Immunotherapy of leukemia L1210 cells after neuraminidase treatment. J. Natl. Cancer Inst. 49, 107 (1972).
Bekesi, J. G., Roboz, J. P., Walter, L., Holland, J. F.: Stimulation of specific immunity against cancer by neuraminidase-treated tumor cells. Behring Inst. Mitt. 55, 309 (1974).
Doré, J. F., Hadjiyannakis, M. J., Guibout, C., Coudert, A., Marholev, L., Imai, K.: Use of enzyme-treated cell in immunotherapy of a murine leukemia. Lancet 1973 VIII, 600.
Hampe, J. F., Misdorp, W.: Tumors and dysplasias of the mammary gland. Bull. WHO 50, 111 (1974).
Holland, J. F., Bekesi, J. G.: Immunotherapy of human leukemia with neuraminidase-modified cells. Med. Clin. North Am. 60, 539 (1976).
Knop, J., Sedlacek, H. H., Seiler, F. R.: Stimulatory effect of Vibrio cholerae neuraminidase on the antibody response against various antigens. Immunology 34, 181 (1978).
Kollmorgen, G. M., Killion, J. J., Sansing, W. A., et al.: Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guérin. Surgery 79, 202 (1976).
Lüben, G., Sedlacek, H. H., Seiler, F. R.: Quantitative experiments on the cell membrane binding of neuraminidase. Behring Inst. Mitt. 59, 30 (1976).
Nakamura, R. M., Chisari, F. V., Edgington, T. S.: Laboratory tests for diagnosis of autoimmune disease. In: Progress in clinical pathology, p. 177. New York: Grune and Stratton 1975.
Petitou, M., Rosenfeld, G., Sinay, P.: A new assay for cell-bound neuraminidase. Cancer Immunol. Immunother. 2, 135 (1977).
Porwit-Bobr, Z., Slowik, M., Tomecki, J.: Effect of neuraminidase-treated and mitomycin C-treated polyoma tumor cells on the established tumor growth in CBA mice. I. An attempt at evaluation of polyoma tumor destruction using the distribution of lissamine green method. Folia Histochem. Cytochem. (Krakow) 12, 315 (1974).
Ronneberger, H.: Toxicological studies with therapeutically applicable Vibrio cholerae neuraminidase. Dev. Biol. Stand. 38, 413 (1978).
Schermer, S.: Blutmorphologie der Laboratoriumstiere, 2. Aufl., p. 85. New York: Johann Ambrosius 1958.
Schick, H. J., Zilg, H.: Production and quality control of therapeutically applicable Vibrio cholerae neuraminidase (VCN). Dev. Biol. Stand. 38, 81 (1978).
Sedlacek, H. H., Seiler, F. R.: Demonstration of Vibrio cholerae neuraminidase (VCN) on the cell membrane of neuraminidasetreated cells. Behring Inst. Mitt. 55, 254 (1974).
Sedlacek, H. H., Meesmann, H., Seiler, F. R.: Regression of spontaneous mammary tumors in dogs after injection of neuraminidasetreated tumor cells. Int. J. Cancer 15, 409 (1975).
Sedlacek, H. H., Seiler, F. R., Schwick, H. G.: Neuraminidase and tumor immunotherapy. Klin. Wochenschr. 55, 199 (1977).
Sedlacek, H. H., Seiler, F. R.: Spontaneous mammary tumors in mongrel dogs: A relevant model to demonstrate tumor therapeutical success by application of neuraminidase. Dev. Biol. Stand. 38, 399 (1978a).
Sedlacek, H. H., Seiler, F. R.: Effect of Vibrio cholerae neuraminidase on the cellular immune response in vivo. In: Immunotherapy of Malignant Diseases. Rainer, H., Borberg, H., Mishler, J. M., Schäfer, U. (eds.), p. 268. Stuttgart: Schattauer 1978b.
Seiler, F. R., Sedlacek, H. H.: Alterations of immunological phenomena by neuraminidase: Marked rise in the number of lymphocytes forming rosettes or bearing immunoglobulin receptors. Behring Inst. Mitt. 55, 258 (1974).
Seiler, F. R., Sedlacek, H. H.: Chessboard vaccination: A pertinent approach to immunotherapy of cancer with VCN and tumor cells? In: Immunotherapy of Malignant Diseases. Rainer, H., Borberg, H., Mishler, J. M., Schäfer, U. (eds.), p. 479. Stuttgart: Schattauer (1978).
Simmons, R. L., Rios, A.: Modified tumor cells in the immunotherapy of solid mammary tumors. Med. Clin. North Am. 60, 551 (1976).
Simmons, R. L., Rios, A., Lundgren, G. et al.: Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. Surgery 70, 38 (1971).
Spence, R. J., Simon, R. M., Baker, A. R.: Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 60, 451 (1978).
Wilson, R. E., Sonis, S. T., Godrick, E. A.: Neuraminidase as an adjunct in the treatment of residual systemic tumor with specific immune therapy. Behring Inst. Mitt. 55, 334 (1974).
Author information
Authors and Affiliations
Additional information
The abbreviations used in this work are: VCN, vibrio cholerae neuraminidase; M, mitomycin-treated; M-VCN, treated with mitomycin and VCN; DTH, delayed-type hypersensitivity; PBS, phosphate-buffered saline
Rights and permissions
About this article
Cite this article
Sedlacek, H.H., Weise, M., Lemmer, A. et al. Immunotherapy of spontaneous mammary tumors in mongrel dogs with autologous tumor cells and neuraminidase. Cancer Immunol Immunother 6, 47–58 (1979). https://doi.org/10.1007/BF00206016
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00206016